pre-IPO PHARMA

COMPANY OVERVIEW

At Affinia Therapeutics, our purpose is to develop gene therapies that can have a transformative impact on people affected by devastating genetic diseases. Our proprietary platform enables us to methodically engineer novel AAV vectors and gene therapies that have remarkable tissue targeting and other properties. We are building world-class capabilities to discover, develop, manufacture and commercialize gene therapy products with an initial focus on muscle and central nervous system (CNS) diseases with significant unmet need.


LOCATION

  • Waltham, MA, USA

  • THERAPEUTIC AREAS

  • Musculoskeletal Disease
  • Neurodegenerative Disease
  • Neurological Disorders

  • WEBSITE

    https://www.affiniatx.com


    CAREER WEBSITE

    https://www.affiniatx.com/careers/our-dna/


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments atlas-venture f-prime-capital lonza nea partners-innovation-fund


    PRESS RELEASES


    May 16, 2022

    Affinia Therapeutics Presents New Data at American Society of Gene and Cell Therapy Annual Meeting


    Mar 8, 2022

    Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors


    Oct 6, 2021

    Affinia Therapeutics Appoints Carole Faig to Board of Directors


    Oct 6, 2021

    Affinia Therapeutics Appoints Carole Faig to Board of Directors


    Sep 8, 2021

    Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group


    For More Press Releases


    Google Analytics Alternative